- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02339545
Coronary Flow Reserve Following Orbital Atherectomy
Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an acute, observational, prospective, multi-center clinical study, evaluating coronary flow reserve (CFR) using the Volcano FloWire®. Subjects will be evaluated after treatment with orbital atherectomy and stenting of de-novo severely calcified lesions, due to coronary artery disease.
Subjects who undergo successful revascularization using the Diamondback 360® Coronary Orbital Atherectomy System (OAS) and stenting are eligible for enrollment. Coronary blood flow of enrolled subjects will be measured with the Volcano FloWire®, Doppler velocity data recorded intra-procedurally, and major adverse cardiac events (MACE) assessed at 24 hours or at discharge, whichever is earlier.
Determination of CFR by Doppler flow measurements can assess physiological changes in the distal vascular bed. The primary endpoint of this study will evaluate coronary flow reserve after successful treatment of severely calcified coronary lesions using OAS and stent deployment. The secondary endpoint will measure the occurrence of post-procedural Major Adverse Cardiac Events (MACE), including cardiac death, acute myocardial infarction (Q wave or non-Q wave), and target vessel revascularization.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Chandler Regional Medical Center and Mercy Gilbert Medical Center
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Hospital
-
-
New York
-
Roslyn, New York, United States, 11576
- St. Francis Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Subjects must meet all inclusion criteria and no exclusion criteria to be eligible to participate in the study.
Inclusion Criteria
- Subjects must be at least 18 years of age.
- Subjects must be scheduled for percutaneous coronary intervention involving stent deployment in de novo coronary lesions.
- The target vessel must be a de-novo coronary artery with a severely calcified lesion.
- The target vessel reference diameter must be ≥ 2.0mm and ≤ 4.0 mm.
- The lesion length must not exceed 40 mm.
- The target vessel must have a thrombolysis in myocardial infarction (TIMI) flow 3 at baseline.
- The target lesion must have fluoroscopic, intravascular ultrasound (IVUS) or optical coherence tomograph (OCT) evidence of severe calcium deposit at the lesion site based on the protocol definition.
- The lesion must be crossable with the ViperWire Advance® coronary guide wire.
- Successful revascularization using OAS and stent deployment as demonstrated by no evidence of stent dissection and no more than 50% stenosis proximal to the stent.
Exclusion Criteria
- Inability to understand the study or a history of non-compliance with medical advice.
- Unwilling or unable to sign the informed consent form (ICF).
- History of any cognitive or mental health status that would interfere with study participation.
- Currently enrolled in any pre-approval investigational study. Note: This does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints.
- Female subjects who are pregnant or planning to become pregnant within the study period.
- Previous myocardial infarction of the target vessel.
- Known sensitivity to contrast media, which cannot be adequately pre-medicated.
- Diagnosed with chronic renal failure or has a serum creatinine level > 2.5 mg/dl.
- History of a stroke or transient ischemic attack (TIA) within six (6) months of the procedure.
- Active peptic ulcer or upper gastrointestinal (GI) bleeding within six (6) months of the procedure.
- Wall motion abnormality in the intended vessel target zone.
- Severe chronic obstructive pulmonary disease (COPD), asthma or current use of the medication: aminophylline.
- 2nd or 3rd degree atrioventricular (AV) block.
- Evidence of current left ventricular ejection fraction (LVEF) ≤45% (where current is defined as the latest LVEF measurement completed within the last 6 months).
- New York Heart Association (NYHA) class III or IV heart failure.
- Previous coronary artery bypass surgery.
- Known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
- Severe aortic stenosis.
- Severe left ventricular hypertrophy.
- Subject with angiographically confirmed evidence of more than 1 lesion requiring intervention.
- Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line quantitative coronary analysis (QCA).
- Target vessel has angiographically visible or suspected thrombus.
Target vessel has a stent from previous PCI unless:
- The stent was implanted greater than 30 days prior to the treatment, and
- The stent has no higher than 30% in-stent stenosis, and
- The stent is on a different branch than the target lesion.
- Target vessel is excessively tortuous.
- Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion.
- Target lesion is a bifurcation.
- Target lesion has a ≥ 1.5 mm side branch.
- Angiographic evidence of a dissection prior to initiation of orbital atherectomy device (OAD).
- Angiographic evidence of MACE during procedure.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
All Enrolled Subjects
All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coronary Flow Reserve (CFR)
Time Frame: Intra-procedurally following successful stent placement. Average procedure time 56 minutes.
|
CFR was measured after successful percutaneous coronary intervention (PCI) treatment of severely calcified coronary lesions.
It was calculated from coronary blood flow velocity measurements, which were derived from Doppler-velocity wire data recorded in real time.
The CFR formula utilized was APVp/APVb, where APVb is the average peak velocity at baseline and APVp is peak hyperemia.
|
Intra-procedurally following successful stent placement. Average procedure time 56 minutes.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Cardiac Events (MACE)
Time Frame: At 24 hours or at time of hospital discharge, whichever occurred first
|
MACE: cardiac death, acute myocardial infarction (Q wave or non-Q wave), or target vessel revascularization.
|
At 24 hours or at time of hospital discharge, whichever occurred first
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nabil Dib, MD, Dignity Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLN-0006-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Coronary Orbital Atherectomy plus Stenting
-
Erasmus Medical CenterRecruitingVascular Calcification | Tomography, Optical Coherence | Treatment Outcome | Coronary Angiography | Humans | Vascular Calcification* / Diagnostic Imaging | Atherectomies, Coronary | Coronary Intervention, Percutaneous | Vascular Calcification* / TherapyNetherlands
-
Cardio Flow, Inc.Libra MedicalCompletedPeripheral Arterial DiseaseUnited States
-
SS Annunziata Hospital, SaviglianoNot yet recruitingMyocardial Infarction | Coronary Artery Disease
-
Abbott Medical DevicesCompletedPeripheral Artery DiseaseUnited States
-
Cardio Flow, Inc.Libra MedicalCompletedPeripheral Arterial DiseaseUnited States
-
Abbott Medical DevicesCompletedCoronary Artery DiseaseUnited States
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.Enrolling by invitationCalcification of Coronary ArteryChina
-
Centre Recherche Cardio Vasculaire AlpesRecruitingCoronary Calcification | AngiographyFrance
-
Abbott Medical DevicesCompletedPeripheral Artery Disease | Critical Limb IschemiaUnited States
-
Columbia UniversityCompletedCoronary Artery Disease (CAD)United States